Medical Cannabis Prescribing Suite — Curaleaf Formulary April 2026

1. Patient

2. Indication

3. Medications

4. Recommendation

Patient assessment

For specialist prescribers only. All prescriptions must comply with UK Schedule 2 regulations (MDR 2001). Products from the Curaleaf Laboratories April 2026 formulary.

Age

Biological sex

Prior cannabis exposure

Contraindications / cautions — select all that apply

Personal/family Hx psychosis

Pregnant / breastfeeding

Under 18

Cardiovascular disease

Severe hepatic impairment

Substance dependence Hx

Bipolar disorder

Regular driver / HGV

Clinical indication

Primary indication

Previous treatments tried (document for NICE compliance)

Patient goals

Preferred route of administration

Oral oil / capsule

Vaporisation (flower)

Liquid vape (QUE)

Pastille / sublingual

Current medications & interactions

Current medications — select all that apply

Warfarin / anticoagulants

SSRIs / SNRIs

Benzodiazepines

Opioids

Antiepileptics (AEDs)

Antipsychotics

Statins

Immunosuppressants

Metformin / hypoglycaemics

Beta-blockers

HRT / hormone therapy

Tamoxifen / aromatase inhibitors

Additional medications (free text)

Prescribing recommendation

1. Patient details

2. Outcome scores

3. Safety review

4. Decision

Patient & prescription details

This tool guides shared care prescribers through the repeat review process. It does not replace clinical judgement. If in doubt, refer back to the initiating specialist.

Patient name / ID

Date of review

Prescriber name

Prescriber role

Indication

Duration of treatment

Current prescription (product, dose, frequency)

Initiating specialist

Has the patient been seen by the initiating specialist in the last 6 months?

Patient-reported outcome measures

Enter today's scores and baseline scores where known. Scores are automatically interpreted. Leave blank if not applicable.

Pain NRS0 = no pain · 10 = worst

Baseline

Today

—

Meaningful improvement = ≥2 point reduction and ≥30% reduction from baseline.

PSQI — sleep0–21 · higher = worse · >5 = poor

Baseline

Today

—

PSQI ≤5 is the normal range. Score >5 persisting at review warrants product or dose review.

GAD-7 — anxiety0–4 minimal · 5–9 mild · 10–14 mod · 15+ severe

Baseline

Today

—

Worsening anxiety on cannabis — especially high-THC — is a red flag. Increase ≥5 points = urgent specialist review.

PHQ-9 — mood0–4 minimal · 5–9 mild · 10+ moderate/severe

Baseline

Today

—

PHQ-9 ≥10 at review, or worsening by ≥5 points, requires clinical assessment before reauthorising.

PGIC — global impression1 = much better · 4 = no change · 7 = much worse

—

Score 4 (no change) or worse after adequate trial suggests treatment is not working.

CUDIT-R — misuse screen0–32 · ≥8 hazardous · ≥13 probable dependence

Score

—

Complete annually or if misuse suspected. Score ≥13: do not reauthorise without specialist input.

Safety & adverse effect review

Adverse effects since last review — select all that apply

New psychotic symptoms

Suicidal ideation

Chest pain / palpitations

New seizure activity

Worsening mood / depression

Worsening anxiety

Cognitive difficulties

Excessive daytime sedation

Nausea / vomiting

Respiratory symptoms (if vaping)

Driving while impaired concern

No adverse effects

Dependence & misuse screening

Has the patient run out of medication early or requested early supply?

Has the patient requested dose increases outside the agreed titration plan?

Is there evidence of concurrent recreational cannabis use?

Drug interaction re-check — any new medications since last review?

Warfarin / anticoagulants

SSRIs / SNRIs

Benzodiazepines

Opioids

Antiepileptics (AEDs)

Statins

Immunosuppressants

Tamoxifen / aromatase inhibitors

No new medications

Any other clinical concerns

Review decision & documentation